/FPHAF

FPHAF Stock - Faron Pharmaceuticals Oy

Q: What is the analyst price target for FPHAF?

Analyst price target information is not currently available for FPHAF.

Q: What is FPHAF's market cap?

Market capitalization information is not currently available for FPHAF.

Healthcare|Biotechnology|OTC

$3.30+0.00%

+$0.00 (+0.00%) • Feb 11

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $3.63

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for FPHAF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.18

52W High$3.30

52W Low$3.30

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-18,673	$-28,568,000	$-27,426,000	$-21,108,000	$-16,654,000
Net Income	$-25,920	$-30,944,000	$-30,034,000	$-21,194,000	$-16,946,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.00	$-0.34	$-0.38	$-0.29	$-0.27

Company Overview

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Visit Website

Frequently Asked Questions about FPHAF

What is FPHAF's current stock price?

Faron Pharmaceuticals Oy (FPHAF) is currently trading at $3.30 per share. The stock has moved +0.00% today.

What is the analyst price target for FPHAF?

No analyst price targets are currently available for this stock.

What sector is Faron Pharmaceuticals Oy in?

Faron Pharmaceuticals Oy operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is FPHAF's market cap?

Faron Pharmaceuticals Oy has a market capitalization of $0.21 billion, making it a small-cap company.

Does FPHAF pay dividends?

No, Faron Pharmaceuticals Oy does not currently pay a dividend to shareholders.